TYPE Stocks
GROUP Stocks
BASE
MRNA
SECOND
US Dollar
<% (signals.list.current.rate).substr(0,7) %>
<% (signals.list.current.absolute).substr(0,9) %>
(<% signals.list.current.percentage|toFixed:2 %>%)
OPEN
<% (signals.list.current.openrate).substr(0,9) %>
HIGH
<% (signals.list.current.high).substr(0,9) %>
LOW
<% (signals.list.current.low).substr(0,9) %>
MRNA Signals
DON'T WANT TO MISS ANY SIGNAL? GO PREMIUM
ACCESS ALL FX, COMMODITIES & CRYPTO SIGNALS. GO PREMIUM
<% signal.status %>
<% signal.analyst %>
Long Term
Entry Price
Stop Loss
Take Profit
PREMIUM ONLY
<% signal.stopLoss %>
N/A
PREMIUM ONLY
<% signal.takeProfit %>
N/A
PREMIUM ONLY
<% signal.analyst %>
<% signal.comment %>
Description
<% signal.description %>
MRNA Signals & Technical Analysis
Last Updated: <% indicators.interval.updated|date:'MMM d, y h:mm:ss a' %>
Market Trend
Strong Sell
Sell
Neutral
Buy
Strong Buy
Loading Market Trend ...
Market Sentiment
BUY: <% indicators.sentiment.buy.length %>
SELL: <% indicators.sentiment.sell.length %>
NEUTRAL: <% indicators.sentiment.neutral.length %>
Strong Sell
Sell
Neutral
Buy
Strong Buy
Trend Indicators
NAME
VALUE
ACTION
Bollinger Bands
UPPER: <% indicators.data[indicators.interval.active].bbands.value.upper %>
MIDDLE: <% indicators.data[indicators.interval.active].bbands.value.middle %>
LOWER: <% indicators.data[indicators.interval.active].bbands.value.lower %>
Sell
Buy
Parabolic SAR
<% indicators.data[indicators.interval.active].sar.value %>
Sell
Buy
Standard Deviation
<% indicators.data[indicators.interval.active].stddev.value %>
High Volatility
Low Volatility
Oscillators
NAME
VALUE
ACTION
RSI(14)
<% indicators.data[indicators.interval.active].rsi.value %>
Sell
Buy
MACD(12,26)
<% indicators.data[indicators.interval.active].macd.value %>
Buy
Sell
Neutral
ATR
<% indicators.data[indicators.interval.active].atr.value %>
High Volatility
Low Volatility
STOCH(9,6)
<% indicators.data[indicators.interval.active].stochastics.value %>
Buy
Sell
ADX
<% indicators.data[indicators.interval.active].adx.value %>
High Volatility
Low Volatility
Moving Averages
PERIOD
SIMPLE
EXPONENTIAL
MA5
<% indicators.data[indicators.interval.active].sma5.value %>
Buy
Sell
<% indicators.data[indicators.interval.active].ema5.value %>
Buy
Sell
MA10
<% indicators.data[indicators.interval.active].sma10.value %>
Buy
Sell
<% indicators.data[indicators.interval.active].ema10.value %>
Buy
Sell
MA20
<% indicators.data[indicators.interval.active].sma20.value %>
Buy
Sell
<% indicators.data[indicators.interval.active].ema20.value %>
Buy
Sell
MA50
<% indicators.data[indicators.interval.active].sma50.value %>
Buy
Sell
<% indicators.data[indicators.interval.active].ema50.value %>
Buy
Sell
MA100
<% indicators.data[indicators.interval.active].sma100.value %>
Buy
Sell
<% indicators.data[indicators.interval.active].ema100.value %>
Buy
Sell
Pivot
PIVOT
CLASSIC
FIBONACCI
CAMARILLA
WOODIE
S3
<% indicators.data[indicators.interval.active].pp.data.result.classic.s3 %>
<% indicators.data[indicators.interval.active].pp.data.result.fibonacci.s3 %>
<% indicators.data[indicators.interval.active].pp.data.result.camarilla.s3 %>
<% indicators.data[indicators.interval.active].pp.data.result.woodie.s3 %>
S2
<% indicators.data[indicators.interval.active].pp.data.result.classic.s2 %>
<% indicators.data[indicators.interval.active].pp.data.result.fibonacci.s2 %>
<% indicators.data[indicators.interval.active].pp.data.result.camarilla.s2 %>
<% indicators.data[indicators.interval.active].pp.data.result.woodie.s2 %>
S1
<% indicators.data[indicators.interval.active].pp.data.result.classic.s1 %>
<% indicators.data[indicators.interval.active].pp.data.result.fibonacci.s1 %>
<% indicators.data[indicators.interval.active].pp.data.result.camarilla.s1 %>
<% indicators.data[indicators.interval.active].pp.data.result.woodie.s1 %>
PP
<% indicators.data[indicators.interval.active].pp.data.result.classic.pp %>
<% indicators.data[indicators.interval.active].pp.data.result.fibonacci.pp %>
<% indicators.data[indicators.interval.active].pp.data.result.camarilla.pp %>
<% indicators.data[indicators.interval.active].pp.data.result.woodie.pp %>
R1
<% indicators.data[indicators.interval.active].pp.data.result.classic.r1 %>
<% indicators.data[indicators.interval.active].pp.data.result.fibonacci.r1 %>
<% indicators.data[indicators.interval.active].pp.data.result.camarilla.r1 %>
<% indicators.data[indicators.interval.active].pp.data.result.woodie.r1 %>
R2
<% indicators.data[indicators.interval.active].pp.data.result.classic.r2 %>
<% indicators.data[indicators.interval.active].pp.data.result.fibonacci.r2 %>
<% indicators.data[indicators.interval.active].pp.data.result.camarilla.r2 %>
<% indicators.data[indicators.interval.active].pp.data.result.woodie.r2 %>
R3
<% indicators.data[indicators.interval.active].pp.data.result.classic.r3 %>
<% indicators.data[indicators.interval.active].pp.data.result.fibonacci.r3 %>
<% indicators.data[indicators.interval.active].pp.data.result.camarilla.r3 %>
<% indicators.data[indicators.interval.active].pp.data.result.woodie.r3 %>
About (MRNA) Moderna, Inc.
Company Overview
Moderna, Inc. (NASDAQ: MRNA), headquartered in Cambridge, Massachusetts, is a pioneering biotechnology company that specializes in drug discovery and development based on messenger RNA (mRNA) technology. Founded in 2010, Moderna's innovative approach aims to harness the body’s own biological processes to create transformative medicines for various diseases. The company gained worldwide recognition for its rapid development of a COVID-19 vaccine, which became a vital tool in combating the pandemic.Market Position
As a leader in mRNA technology, Moderna has positioned itself at the forefront of the biotechnology industry. Its COVID-19 vaccine, Spikevax, was among the first to receive Emergency Use Authorization from the U.S. Food and Drug Administration (FDA), contributing significantly to the company's growth and visibility. Beyond the pandemic, Moderna continues to expand its mRNA platform, focusing on therapeutic vaccines for infectious diseases, oncology, rare diseases, and autoimmune disorders. The company's commitment to research and development has solidified its status as an innovative player in the biotechnology sector.Key Financial Highlights
Moderna's financial performance has reflected its rapid growth trajectory, driven primarily by vaccine sales and strategic collaborations. In 2021, the company reported record revenues exceeding $18 billion, significantly bolstered by the global demand for its COVID-19 vaccine. The company maintains a robust balance sheet with substantial cash reserves, allowing for continued investment in research and development. Looking ahead, Moderna aims to diversify its product pipeline, with several candidates in various stages of clinical development, which positions the company for sustainable long-term growth.Industry Outlook
The biotechnology industry continues to thrive, with an increasing focus on personalized medicine and innovative treatment modalities. Moderna's unique mRNA technology platform places it in a strong position to capitalize on emerging trends within the sector. As the company advances its pipeline and expands its global reach, it is well-equipped to address unmet medical needs, further solidifying its role as a leader in the biopharmaceutical landscape.Related Stocks
Sidebar rates
Related Pairs
Multi Charts
- <% signal.pair %>
<% signals.active.Current.rate.substr(0,7) %>
<% signals.active.Current.absolute.substr(0,7) %> (<% signals.active.Current.percentage %>%)
